KRMD

Business Context and Reporting Period

Company: Repro-Med Systems, Inc. (Note: Input metadata referenced "KORU Medical Systems," but the filing text identifies the registrant as Repro-Med Systems, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: February 28, 2010
Business Overview: The Company designs, manufactures, and markets proprietary medical devices for emergency medical applications and ambulatory infusion therapy. Primary products include the FREEDOM60(R) Syringe Infusion System and the RES-Q-VAC(R) Emergency Airway Suction System. The Company is a smaller reporting company incorporated in New York.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 9.8% to $3.77 million, driven primarily by a 23.3% increase in FREEDOM60 sales ($2.81 million vs. $2.27 million). This growth was attributed to increased Medicare reimbursement for subcutaneous immune globulin (SCIG) and new international distribution in Finland.
• Profitability Decline: Despite revenue growth, Net Income decreased 13.7% to $889,444. This was caused by a $382,307 increase in Selling, General & Administrative (SG&A) expenses due to marketing efforts and a reduction in the income tax benefit from $306,000 to $226,984.
• Product Mix Shift: Infusion Therapy sales now represent 75.63% of total revenue (up from 67.62%), while Medical Suction sales declined 7.6% to $871,814. Non-core product lines (Gynecological and Contract Manufacturing) decreased by 44.5%.
• Liquidity Improvement: Working capital improved significantly to $1.98 million, supported by a cash balance increase of $294,174 and the recognition of deferred tax assets.

Guidance, Outlook, and Risks

• Outlook: Management expects continued growth in the SCIG market and anticipates that the new Hizentra(R) drug formulation will create additional opportunities for the FREEDOM60 system in fiscal year 2011. The Company believes current capital and cash flow are sufficient to meet financial needs for the next twelve months.
• Regulatory Status: A revised FDA 510(k) application for the FREEDOM60 was not accepted due to guideline changes; the Company is negotiating to submit a new application. The RES-Q-VAC(R) is the only portable device believed to comply with CDC directives for SARS control.
• Key Risks:
  • Key Personnel: The Company is heavily dependent on Andrew Sealfon (President/CEO/R&D), who has no life insurance coverage.
  • Reimbursement: Sales are heavily reliant on Medicare reimbursement codes; changes could adversely affect sales.
  • Competition: Potential entry of competitors with greater resources or new drug technologies (e.g., Hyaluronidase) could impact market share.
  • Related Party Transactions: Significant debt exists with related parties (President and Directors), including a $100,000 loan from the President and a remaining balance of approximately $555,000 from a Director.

Investor Verification Checklist

• Revenue Concentration: Verify the sustainability of the 23.3% growth in FREEDOM60 sales and the reliance on specific Medicare reimbursement codes (E0779).
• Regulatory Approvals: Confirm the status of the pending FDA 510(k) application for the updated FREEDOM60 and new needle sets.
• Related Party Debt: Review the terms and repayment schedules of the $689,966 in long-term debt, a significant portion of which is owed to the President and a Director.
• Key Person Risk: Assess the succession plan given the Company's dependence on Andrew Sealfon for R&D, sales, and finance.
• Deferred Tax Assets: Verify the realization of the $532,984 deferred tax asset, which was fully recognized in 2010 after a valuation allowance was removed in 2009.